


T24 proliferation: 2 nM Gemcitabine +/- 5 μ M SAHA

Figure 1A

Best Available Copy

T24 viability: 2nM Gemcitabine + 5 uM SAHA




Figure 1B

Best Available Copy

LNCAP proliferation: 2nM Gemcitabine +/- 5 uM SAHA




Figure 2A

Best Available Copy

LNCAP viability: 2nM Gemcitabine +/- 5 uM SAHA






Figure 2B

Best Available Copy

T24 proliferation: 8-day treatment with 200 nM AZ +/- 5 uM SAHA



T24 cell viability: 8-day treatment with 200 nM AZ +/- 5 uM SAHA



Best Available Copy




Figure 4A

Best Available Copy




Figure 4B

Best Available Copy




Figure 5

Best Available Copy





Figure 6

Best Available Copy

**Figure 7**

Best Available Copy




Figure 8

Best Available Copy




Figure 9

Best Available Copy

Percent Inhibition of LNCap Cells Treated
with SAHA and Docetaxel




Figure 11

Best Available Copy